Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 5/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958586 | 0.83 | NPC1 (0.62) | SPRTP53NPC1RAB9ALMNA | |
| SCHEMBL23211945 | 0.80 | DRD2 (0.42) | SPRTP53NPC1RAB9ALMNA | |
| SCHEMBL21381647 | 0.80 | DRD2 (0.42) | SPRTP53NPC1RAB9ALMNA | |
| SCHEMBL4156475 | 0.78 | NOTUM (0.43) | SPRTP53NPC1RAB9ALMNA | |
| SCHEMBL4156476 | 0.78 | NOTUM (0.43) | SPRTP53NPC1RAB9ALMNA | |
| SCHEMBL826363 | 0.78 | PDE4B (0.56) | TP53LMNAMAPT | |
| SCHEMBL21381706 | 0.78 | PDE4B (0.56) | TP53LMNAMAPT | |
| SCHEMBL3183837 | 0.77 | RAB9A (0.67) | SPRTP53NPC1RAB9ALMNA | |
| SCHEMBL3183827 | 0.77 | RAB9A (0.67) | SPRTP53NPC1RAB9ALMNA | |
| SCHEMBL3184817 | 0.77 | RAB9A (0.67) | SPRTP53NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019180185-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | WO | disclosed |
| US-8343763-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120149742-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143297-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110098328-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2307412-A2 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7846954-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100004300-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010002956-A2 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | SPR 3409/4885TP53 4672/4885NPC1 433/4885 |
| US-20120149742-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | SPR 3614/4885TP53 4296/4885NPC1 415/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | SPR 3409/4885TP53 4672/4885NPC1 433/4885 |
| US-20100004300-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | SPR 3614/4885TP53 4296/4885NPC1 415/4885 |
| US-20110098328-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | SPR 3614/4885TP53 4296/4885NPC1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.